Skip to main content

Peer Review reports

From: Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015–04 (PANGEA-Breast) study

Original Submission
22 Jun 2022 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
31 Aug 2022 Reviewed Reviewer Report - Leticia Moreno-fierros
11 Oct 2022 Reviewed Reviewer Report
25 Oct 2022 Author responded Author comments - Luis de la Cruz-Merino
Resubmission - Version 3
25 Oct 2022 Submitted Manuscript version 3
26 Oct 2022 Author responded Author comments - Luis de la Cruz-Merino
Resubmission - Version 4
26 Oct 2022 Submitted Manuscript version 4
27 Oct 2022 Author responded Author comments - Luis de la Cruz-Merino
Resubmission - Version 5
27 Oct 2022 Submitted Manuscript version 5
6 Nov 2022 Reviewed Reviewer Report - Leticia Moreno-fierros
20 Nov 2022 Reviewed Reviewer Report
21 Nov 2022 Author responded Author comments - Luis de la Cruz-Merino
Resubmission - Version 6
21 Nov 2022 Submitted Manuscript version 6
22 Nov 2022 Reviewed Reviewer Report - Leticia Moreno-fierros
Resubmission - Version 7
Submitted Manuscript version 7
Publishing
24 Nov 2022 Editorially accepted
3 Dec 2022 Article published 10.1186/s12885-022-10363-3

You can find further information about peer review here.

Back to article page